{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:19:28Z","timestamp":1782926368977,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007817","name":"Alcon Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011377","name":"Glaucoma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ogla.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:27:46Z","timestamp":1741901266000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of Systemic Calcium Channel Blocker Use with Visual Field Progression in a Large Real-World Cohort from Glaucoma Clinics"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2804","authenticated-orcid":false,"given":"Giovanni","family":"Montesano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7772-5929","authenticated-orcid":false,"given":"Alessandro","family":"Rabiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2907-6992","authenticated-orcid":false,"given":"David F.","family":"Garway-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-6912","authenticated-orcid":false,"given":"Dun Jack","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-5005","authenticated-orcid":false,"given":"Gus","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-4847","authenticated-orcid":false,"given":"Giovanni","family":"Ometto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-3902","authenticated-orcid":false,"given":"David P.","family":"Crabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-8585","authenticated-orcid":false,"given":"Anthony P.","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2025.03.002_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.294.4.466","article-title":"Hypertension in adults across the age spectrum: current outcomes and control in the community","volume":"294","author":"Lloyd-Jones","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ogla.2025.03.002_bib2","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1111\/bcp.13709","article-title":"The \u2018top 100\u2019 drugs and classes in England: an updated \u2018starter formulary\u2019 for trainee prescribers","volume":"84","author":"Audi","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ogla.2025.03.002_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ogla.2025.03.002_bib4","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bjo.2004.053397","article-title":"Systemic hypertension and glaucoma: mechanisms in common and co-occurrence","volume":"89","author":"Langman","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ceo.12763","article-title":"Associations between chronic systemic diseases and primary open angle glaucoma: an epidemiological perspective","volume":"45","author":"Tham","year":"2017","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib7","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.ophtha.2007.03.047","article-title":"Systemic antihypertensive medication and incident open-angle glaucoma","volume":"114","author":"Muskens","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ophtha.2018.01.007","article-title":"Systemic medication associations with presumed advanced or uncontrolled primary open-angle glaucoma","volume":"125","author":"Zheng","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of systemic medication use with glaucoma and intraocular pressure: the European eye epidemiology consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/jamaophthalmol.2023.3877","article-title":"Calcium Channel blocker use and associated glaucoma and related traits among UK biobank participants","volume":"141","author":"Kastner","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ogla.2024.06.003","article-title":"Long term systemic use of Calcium Channel blockers and incidence of primary open angle glaucoma","volume":"7","author":"Tavakoli","year":"2024","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2025.03.002_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ophtha.2020.07.051","article-title":"Association of antihypertensive medication with retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness","volume":"128","author":"Chong","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib13","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1167\/iovs.19-27984","article-title":"Association of systemic medication exposure with glaucoma progression and glaucoma suspect conversion in the groningen longitudinal glaucoma study","volume":"60","author":"Pappelis","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2025.03.002_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00061198-199904000-00006","article-title":"Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure","volume":"8","author":"Koseki","year":"1999","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ogla.2025.03.002_bib15","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.ophtha.2008.05.015","article-title":"A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure","volume":"115","author":"Koseki","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s004170050203","article-title":"Risk factors for visual field damage progression in normal-tension glaucoma eyes","volume":"237","author":"Daugeliene","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00061198-199812000-00004","article-title":"Clinical factors associated with progression of normal-tension glaucoma","volume":"7","author":"Ishida","year":"1998","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ogla.2025.03.002_bib18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/bjophthalmol-2019-315052","article-title":"Progression from ocular hypertension to visual field loss in the English hospital eye service","volume":"104","author":"Kelly","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1600-0420.1997.tb00392.x","article-title":"A new generation of algorithms for computerized threshold perimetry, SITA","volume":"75","author":"Bengtsson","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ogla.2025.03.002_bib20","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2017.04.035","article-title":"Evidence-based criteria for assessment of visual field reliability","volume":"124","author":"Yohannan","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaophthalmol.2014.4237","article-title":"Measurement precision in a series of visual fields acquired by the standard and fast versions of the Swedish interactive thresholding algorithm: analysis of large-scale data from clinics","volume":"133","author":"Saunders","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bjophthalmol-2012-301827","article-title":"Practical landmarks for visual field disability in glaucoma","volume":"96","author":"Saunders","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/opo.12328","article-title":"Cases of advanced visual field loss at referral to glaucoma clinics - more men than women?","volume":"37","author":"Crabb","year":"2017","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ogla.2025.03.002_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/opo.12187","article-title":"Disease severity in newly diagnosed glaucoma patients with visual field loss: trends from more than a decade of data","volume":"35","author":"Boodhna","year":"2015","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ogla.2025.03.002_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1167\/iovs.13-13006","article-title":"Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime","volume":"55","author":"Saunders","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2025.03.002_bib26","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/s41433-023-02567-z","article-title":"Measures of multiple deprivation and visual field loss in glaucoma clinics in England: lessons from big data","volume":"37","author":"Rathore","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.ogla.2025.03.002_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ogla.2025.03.002_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ogla.2025.03.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ogla.2025.03.002_bib30","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package \u201cdagitty\u201d","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ogla.2025.03.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ogla.2025.03.002_bib32","first-page":"1","article-title":"Mice: multivariate imputation by chained Equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ogla.2025.03.002_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.13.4.15","article-title":"Estimating the distribution of true rates of visual field progression in glaucoma","volume":"13","author":"Montesano","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ogla.2025.03.002_bib34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automatic Control"},{"key":"10.1016\/j.ogla.2025.03.002_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/aje\/kws412","article-title":"The table 2 fallacy: presenting and interpreting confounder and modifier coefficients","volume":"177","author":"Westreich","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ogla.2025.03.002_bib36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.ophtha.2020.03.029","article-title":"Visual field outcomes from the multicenter, randomized controlled laser in glaucoma and ocular hypertension trial (LiGHT)","volume":"127","author":"Wright","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.03.002_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ajo.2023.02.008","article-title":"Five-year visual field outcomes of the HORIZON trial","volume":"251","author":"Montesano","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib38","series-title":"Extending the linear model with R (texts in statistical science)","author":"Faraway","year":"2005"},{"key":"10.1016\/j.ogla.2025.03.002_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.preteyeres.2010.09.002","article-title":"Use of calcium channel blockers for glaucoma","volume":"30","author":"Araie","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ogla.2025.03.002_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00061198-199810000-00002","article-title":"The effect of nilvadipine, a calcium-Channel Blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma","volume":"7","author":"Yamamoto","year":"1998","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ogla.2025.03.002_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1006423919238","article-title":"Changes in optic nerve head blood flow and retrobular hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma","volume":"23","author":"Tomita","year":"1999","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2003.037671","article-title":"Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma","volume":"89","author":"Luksch","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib44","article-title":"Mitochondria damaged by oxygen glucose deprivation can be restored through activation of the PI3K\/akt pathway and inhibition of calcium influx by amlodipine camsylate","volume":"9","author":"Park","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ogla.2025.03.002_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13812","article-title":"Neuroprotective effect of the calcium channel blocker nilvadipine on retinal ganglion cell death in a mouse ocular hypertension model","volume":"9","author":"Tsuruga","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ogla.2025.03.002_bib46","series-title":"2nd International Adalat Symposium: New Therapy of Ischemic Heart Disease","article-title":"Response of intraocular pressure in normal subjects and glaucoma patients to single and repeated doses of the coronary drug adalat","author":"Schnell","year":"1975"},{"key":"10.1016\/j.ogla.2025.03.002_bib47","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0002-9394(14)71934-8","article-title":"The effect of a calcium-channel blocking agent on intraocular pressure","volume":"96","author":"Monica","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.03.002_bib48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjo.72.3.216","article-title":"Effect of the calcium antagonist nifedipine on intraocular pressure in normal subjects","volume":"72","author":"Kelly","year":"1988","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419625000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419625000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:32:50Z","timestamp":1777696370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419625000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2589419625000432"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2025.03.002","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Systemic Calcium Channel Blocker Use with Visual Field Progression in a Large Real-World Cohort from Glaucoma Clinics","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}